Corient Private Wealth LP Makes New $2.45 Million Investment in PROCEPT BioRobotics Corporation $PRCT

Key Points

• Corient Private Wealth LP acquired 108,403 shares of PROCEPT BioRobotics worth approximately $2.45 million, giving it a 0.19% stake. Institutional investors and hedge funds collectively own 89.46% of the company.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year, but its $0.47 loss per share slightly missed estimates. Shares opened at $21.97, while the stock remains unprofitable with a negative net margin of 32.53%.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $25.09. The company also faces securities-fraud litigation allegations related to inventory levels, handpiece sales and discounting practices, creating additional legal and reputational risks.

Corient Private Wealth LP acquired a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 108,403 shares of the company's stock, valued at approximately $2,448,000. Corient Private Wealth LP owned 0.19% of PROCEPT BioRobotics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Johnson & Johnson bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth about $8,082,263. Pinnacle Associates Ltd. acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at about $3,876,000. DNB Asset Management AS raised its holdings in PROCEPT BioRobotics by 213.9% in the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company's stock valued at $3,132,000 after acquiring an additional 67,848 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in PROCEPT BioRobotics by 69.8% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 174,739 shares of the company's stock worth $5,375,000 after acquiring an additional 71,832 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new stake in shares of PROCEPT BioRobotics during the first quarter worth approximately $1,693,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Up 5.1%

Shares of PRCT opened at $21.97 on Thursday. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $41.51. The firm's 50 day moving average is $20.35 and its 200-day moving average is $23.74. The stock has a market capitalization of $1.26 billion, a PE ratio of -11.32 and a beta of 0.91. The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company's quarterly revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.35) earnings per share. Equities research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Larry L. Wood bought 23,900 shares of the business's stock in a transaction dated Friday, August 7th. The stock was purchased at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the transaction, the chief executive officer owned 23,900 shares in the company, valued at $498,315. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PRCT shares. TD Cowen decreased their target price on PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating on the stock in a research report on Wednesday, August 5th. UBS Group cut PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 price target for the company. in a report on Tuesday, July 28th. Jefferies Financial Group restated a "hold" rating and issued a $20.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. William Blair lowered PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Finally, Truist Financial set a $21.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $25.09.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Analyst sentiment toward PROCEPT BioRobotics was described as mixed, suggesting investors may remain divided on the company’s outlook. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Negative Sentiment: Several law firms publicized a securities fraud class action against PROCEPT BioRobotics and urged investors who purchased shares between February 28, 2024, and February 25, 2026, to seek lead-plaintiff status by September 22, 2026. The repeated announcements increase visibility around the legal risk and may weigh on investor sentiment. Kaplan Fox Urges Investors of PROCEPT BioRobotics Corporation
• Negative Sentiment: The allegations center on surprise weakness in unit handpiece sales, excess customer inventory, and repeated late-quarter bulk discounts. Plaintiffs claim these practices obscured demand problems, inflated recurring-revenue metrics, and pulled forward sales. The related disclosures were cited as contributing to an approximately 18% stock decline during the alleged class period. PROCEPT BioRobotics Corporation Securities Fraud Class Action
• Negative Sentiment: Additional notices allege that management attributed revenue volatility to temporary saline shortages rather than inventory overstocking. These are allegations, not established findings, but the litigation creates potential financial, reputational, and disclosure-related risks for PRCT. Levi & Korsinsky Reminds Shareholders

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.